
|Videos|February 14, 2014
Pazopanib for the Treatment of Soft Tissue Sarcoma
Author(s)Vicki Keedy, MD
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.
Advertisement
Clinical Pearls
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses pazopanib for the treatment of soft tissue sarcoma.
- Pazopanib was recently approved for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy
- Treatment with pazopanib quadrupled progression-free survival compared with placebo
- Drugs to treat soft tissue sarcoma are generally toxic
- Pazopanib is well tolerated, with some instances of extended fatigue
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































